Healthcare entity
Every one of those 1 sits in a single category, regulation. NHS England is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 9 original sources per story, versus 6 across the same-window beat baseline.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. NHS England is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 9 original sources per story, versus 6 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 5.8. We currently track 1 Healthcare story that mention UK Medicines and Healthcare products Regulatory Agency (MHRA), all published on February 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering UK Medicines and Healthcare products Regulatory Agency (MHRA). Shared-story counts are live from our verified record — not editorial picks.
MHRA Suspension
The medicines regulator pauses the trial citing new concerns, halting the primary access route for patients.
Clinical Trial Launch
The UK government and NHS launch a formal clinical trial to gather long-term data on treatment outcomes.
NHS Routine Ban
NHS England ends the routine prescription of puberty blockers for gender dysphoria.
Cass Review Published
Final report recommends puberty blockers only be administered within a research setting due to lack of evidence.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has halted a major clinical trial into puberty blockers for minors following the emergence of new regulatory concerns. This suspension effectively closes the primary legal pathway for gender-distressed youth to access these treatments within the NHS framework.
Source: gazetteherald.co.uk · impartialreporter.com
UK Medicines and Healthcare products Regulatory Agency (MHRA) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
